E mal Injection 150mg/2ml (α-β arteether)

E mal Injection 150mg contains α-β arteether, an advanced artemisinin derivative. This injectable antimalarial is specifically formulated for severe and complicated malaria treatment, providing rapid intervention when oral medications aren’t viable. Its potent formulation effectively combats even resistant malaria parasites.

Uses

E mal Injection 150mg treats severe and complicated malaria cases where oral medication is impractical or ineffective. It’s vital in malaria-endemic regions and for patients with acute, life-threatening malarial infections, particularly when rapid intervention is necessary.

Benefits

• Rapidly clears parasites, often within 24-48 hours
• Highly effective against multidrug-resistant Plasmodium falciparum
• Significantly reduces mortality in severe and cerebral malaria
• Provides fast symptomatic relief and fever reduction
• Suitable for patients unable to take oral medications
• Effective in areas with high antimalarial drug resistance

How It Works

α-β arteether targets malaria parasites by interfering with their ability to detoxify heme, causing toxic free radical accumulation within the parasite. This creates oxidative stress leading to parasite death. The rapid action quickly reduces parasite load, preventing life-threatening complications.

Dosage

Administered intramuscularly by healthcare professionals. Complete the full treatment course even if symptoms improve quickly.

Duration of Action

E mal Injection begins reducing parasite load within hours of administration. Most patients show significant clinical improvement within 24-48 hours. Effects of a single dose typically last 24 hours, requiring daily administration for the full 3-day regimen to prevent recrudescence.

Side Effects

Common side effects include injection site pain, transient nausea, vomiting, dizziness, and mild headache that typically resolve without intervention. Rare severe effects may include allergic reactions (skin rashes, breathing difficulty) and neurological symptoms (ataxia, nystagmus).

Warning

Administer only under close medical supervision in settings equipped to manage severe malaria. Not recommended for prophylaxis or uncomplicated malaria treatable with oral medications. Contraindicated in patients with hypersensitivity to artemisinin derivatives.

Pregnancy and Breastfeeding

Use during pregnancy requires careful benefit-risk evaluation by healthcare professionals. Generally considered safe in second and third trimesters when malaria risks outweigh drug risks. Limited data exists regarding excretion in breast milk; consult healthcare provider before use while breastfeeding.

Interaction

• May enhance QT-prolonging effects of certain medications
• Potential interactions with CYP3A4 inhibitors or inducers
• Caution advised with concurrent antimalarial drugs
• Possible interaction with anticoagulants requiring monitoring
• May affect hormonal contraceptive efficacy

Precaution

Monitor cardiac function during administration. Use with caution in patients with hepatic or renal impairment. Confirm diagnosis before treatment initiation. Patient should remain under observation during treatment course. Follow institutional guidelines for intramuscular injection techniques to prevent complications.

Important Information

Use as part of comprehensive malaria treatment strategy. Proper diagnosis through blood smear or rapid tests essential before treatment. Monitor parasitemia levels and clinical response during treatment. Follow-up with oral antimalarials may be necessary to ensure complete clearance and prevent recrudescence.